What is the Annual Allogeneic Cell Therapies Summit?
The 7th Annual Allogeneic Cell Therapies Summit was the premier forum uniting cell therapies to advance accessible off-the-shelf approaches. Spanning from preclinical development to manufacturing to commercialization, this year's content provided you with valuable insights at all stages of development.
This was your opportunity to hear the latest updates across a diverse set of cell developers, whether it is Gamma Delta T cells with IN8Bio, CAR-Ts with Adicet Bio, or NK cells with Senti Biosciences!
As the leading meeting for allogeneic cell therapies, you networked with large pharma including Takeda, AstraZeneca and Bristol Myers Squibb, whilst also joining top biotech companies like Adicet Bio and Caribou Bio, alongside new emerging companies such as Shinobi Therapeutics and Tr1x.
Who Attended this Summit?
What Topics Were Covered?
Solid Tumour Breakthroughs: Attendees heard from NKILT Therapeutics, and Synaptimmune on how allogeneic therapies are targeting the tumour microenvironment to unlock entirely new indications.
Manufacturing at Scale: As the pressure builds to make these therapies commercially viable, attendees learnt how Tevogen and Cell BioEngines are navigating the complexities of scalable, high-quality manufacturing.
New Regulatory Horizons: With evolving frameworks and novel allogeneic approaches entering the clinic, Bristol Myers Squibb and Takeda revealed how they were preparing to accelerate approval timelines in 2025.
Beyond Oncology: In 2025, attendees broadened their scope by discovering how Biosyngen was leveraging allogeneic platforms to address autoimmune disorders.
Responding to industry demand, this year's agenda featured two in-depth workshops on critical topics such as mechanisms of allo-rejection, strategic donor sourcing and selection, controlled cell expansion, and tackling solid tumor challenges.
We streamlined our content into two brand-new tracks to reflect your contemporary needs.
For the first time, attendees heard from Shinobi Therapeutics, Mendus, Tr1x Bio, Cell BioEngines, and Biosyngen - all making their speaking debuts at this must-attend global event.
What Was New for 2025?
Why Attend?
Building on the milestones met this year, 2026 is likely to continue the momentum to transform the future of allogeneic therapies.
Recent headlines include:
- Allogene Therapeutics advances into autoimmune disease with their next-generation allogeneic CAR-T.
- Imugene secures FDA fast-track designation for CAR T-cell therapy to combat blood cancer.
- Orca Bio's T-cell therapy doubles blood cancer patient survivals compared to standard stem cell transplants.
Who Was Speaking?
I'd like to Register my Interest?
To register your interest simply get in touch at [email protected] to discuss options for either next year's event, or other events in the Cell Therapy Series.